Among recent therapeutic advancements, immune checkpoint inhibitors—particularly those that inhibit the PD-1/PD-L1 pathway, such as nivolumab—have demonstrated improved survival outcomes in patients with advanced NSCLC who have experienced disease progression following platinum-based chemotherapy regimens [2]. Here, CD274 is linked to non-small cell lung carcinoma.